Bronchiectasis

8
Pipeline Programs
6
Companies
8
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
4
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
3 programs
2
1
BI 1291583Phase 31 trial
BI 1291583Phase 21 trial
BI 1291583Phase 21 trial
Active Trials
NCT05846230Active Not Recruiting268Est. Mar 2027
NCT05238675Completed322Est. May 2024
NCT06872892Recruiting1,755Est. Oct 2028
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
AZLIPhase 31 trial
Active Trials
NCT01313624Completed266Est. Jun 2013
Insmed
InsmedBRIDGEWATER, NJ
2 programs
1
280 mg Arikayce™Phase 21 trial
Development of a Canadian Bronchiectasis and NTM DatabaseN/A1 trial
Active Trials
NCT06144996RecruitingEst. Jan 2050
NCT00775138Completed64Est. May 2009
Novartis
NovartisBASEL, Switzerland
2 programs
1
1
QBW251Phase 21 trial
T-326 InhalerPhase 1
Active Trials
NCT04396366Terminated42Est. Jun 2023
Bayer
BayerLEVERKUSEN, Germany
1 program
1
T-326 InhalerPhase 11 trial
Active Trials
NCT02563197Completed33Est. Apr 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Boehringer IngelheimBI 1291583
Gilead SciencesAZLI
Boehringer IngelheimBI 1291583
Boehringer IngelheimBI 1291583
NovartisQBW251
Insmed280 mg Arikayce™
BayerT-326 Inhaler
InsmedDevelopment of a Canadian Bronchiectasis and NTM Database

Clinical Trials (8)

Total enrollment: 2,750 patients across 8 trials

NCT06872892Boehringer IngelheimBI 1291583

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

Start: Jun 2025Est. completion: Oct 20281,755 patients
Phase 3Recruiting
NCT01313624Gilead SciencesAZLI

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

Start: Apr 2011Est. completion: Jun 2013266 patients
Phase 3Completed
NCT05846230Boehringer IngelheimBI 1291583

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

Start: Sep 2023Est. completion: Mar 2027268 patients
Phase 2Active Not Recruiting
NCT05238675Boehringer IngelheimBI 1291583

A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

Start: Apr 2022Est. completion: May 2024322 patients
Phase 2Completed
NCT04396366NovartisQBW251

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis

Start: Feb 2021Est. completion: Jun 202342 patients
Phase 2Terminated
NCT00775138Insmed280 mg Arikayce™

Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

Start: Jun 2008Est. completion: May 200964 patients
Phase 2Completed
NCT02563197BayerT-326 Inhaler

Inhalation Flow Rate-study

Start: Nov 2015Est. completion: Apr 201633 patients
Phase 1Completed
NCT06144996InsmedDevelopment of a Canadian Bronchiectasis and NTM Database

Development of a Canadian Bronchiectasis and NTM Database

Start: Jan 2023Est. completion: Jan 2050
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 2,750 patients
6 companies competing in this space